Opinion|Videos|December 29, 2023
Clinical Data on the Approved JAK Inhibitors for Treatment of Myelofibrosis
Author(s)Christine Cooper, RN, BSN, Aaron Gerds, MD, MS
An expert discusses the four FDA-approved JAK inhibitors for myelofibrosis - ruxolitinib, fedratinib, pacritinib, and momelotinib.
Advertisement
Episodes in this series
Advertisement
Advertisement
Advertisement
Trending on CURE
1
Breast Cancer Treatments Awaiting FDA Decisions: 4 to Watch
2
FDA Approves Etcamah Plus CDK4/6 Inhibitor for ESR1-Mutated Breast Cancer
3
What Breast Cancer Survivors Should Know About Weight Loss and Long-Term Health
4
6 Cancer Drugs FDA Approved in August 2026 and What They Mean for You
5